RxDoctor Payments Data

Mohammed Iqbal, MD

Internal Medicine · West Hills, CANPI 1578574596

Payments from drug & device makers

$893in general payments, 2019–2025

Across 36 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$200
  • Novartis$180
  • Medtronic$136
  • Kowa Pharmaceuticals America, Inc.$91
  • Novo Nordisk$88
  • Abbott$58
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$893100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$70,341
Medicare patients
229
Services billed
3,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$130,101
MounjaroTirzepatide64$84,738
JardianceEmpagliflozin54$71,623
EliquisApixaban47$39,645
JanuviaSitagliptin Phosphate30$30,697
XareltoRivaroxaban25$19,480
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$18,293
FarxigaDapagliflozin Propanediol16$18,156
MyrbetriqMirabegron19$17,734
WegovySemaglutide11$17,101
LinzessLinaclotide11$12,237
Dexlansoprazole DrDexlansoprazole21$8,428
Atorvastatin Calcium717$7,812
Rosuvastatin Calcium211$6,535
DuleraMometasone/Formoterol11$4,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$88$147,203121 claims
Lilly USA, LLCMounjaro$14$84,73864 claims
PfizerEliquis$12$39,64547 claims
GSKTrelegy Ellipta$31$18,29313 claims
Astellas Pharma US IncMyrbetriq$21$17,73419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →